You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
京新藥業(002020.SZ)業績快報:2021年度淨利降7.28%至6.06億元
格隆匯 02-25 17:11

格隆匯2月25日丨京新藥業(002020.SZ)披露2021年度業績快報,報吿期內,公司實現營業總收入33.22億元,比上年同期增長1.96%;其中成品藥收入19.14億元,同比下降2.41%;原料藥收入8.14億元,同比增長1.38%;醫療器械收入5.46億元,同比增長21.34%。主要是受藥品集採影響,他汀類製劑及原料藥價格有明顯下降,藥品業務銷售收入同比略有下降;醫療器械國際ODM業務訂單恢復增長,銷售收入同比大幅提升。

報吿期內,公司實現營業利潤、利潤總額和歸屬於上市公司股東的淨利潤分別為6.80億元、6.82億元和6.06億元,分別比上年同期下降11.15%、10.18%和7.28%,主要是對外投資公允價值變動收益同比減少約1億元,非經損益同比下降50%左右。歸屬於上市公司股東的扣除非經常性損益的淨利潤約5.09億,同比增長14.11%,主要是公司通過產品結構調整優化、大產品規劃實施推進、業務結構更加合理;通過精益生產、降本增效的持續深化,管理效能進一步提升,公司主營業務盈利水平實現了穩定增長。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account